Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency
NCT04240054
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is testing a new treatment. It will involve a small group of people, and they will be able to see what treatment they are getting. The first part of the study is to make sure the treatment is safe.
This study is testing a new treatment. It will involve a small group of people, and they will be able to see what treatment they are getting. The first part of the study is to make sure the treatment is safe.
Third Opinion AI Generated Synopsis
Trial Summary
This is a single-arm, open-label phase II study with a safety lead-in phase.
This is a single-arm, open-label phase II study with a safety lead-in phase.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
